X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/galera-shares-tank-after-us-fda-declines-approve-inflammation-disease-drug-2023-08-09/
https://www.globenewswire.com/news-release/2023/02/15/2608650/0/en/Galera-Announces-FDA-Acceptance-and-Priority-Review-of-Avasopasem-NDA-for-Radiotherapy-Induced-Severe-Oral-Mucositis.html
https://www.globenewswire.com//news-release/2022/12/12/2571705/0/en/Galera-Submits-New-Drug-Application-for-Avasopasem-for-Severe-Oral-Mucositis.html
https://www.globenewswire.com/news-release/2022/05/26/2451643/0/en/Galera-Announces-Oral-Presentation-at-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting-Detailing-Results-from-Phase-3-ROMAN-Trial-of-Avasopasem.html
https://www.fiercebiotech.com/biotech/turns-out-galera-s-radiotherapy-drug-did-work-after-all-and-investors-are-thrilled
https://www.fiercebiotech.com/biotech/galera-shares-slide-nearly-70-as-radiotherapy-complication-drug-flunks-out-phase-3
https://www.globenewswire.com/news-release/2021/06/28/2253731/0/en/Galera-Announces-Completion-of-Enrollment-in-Pivotal-455-Patient-Phase-3-Trial-of-Avasopasem-for-Severe-Oral-Mucositis.html
https://www.biospace.com/article/releases/galera-therapeutics-announces-dosing-of-first-patient-in-a-randomized-double-blind-pilot-phase-2-clinical-trial-of-gc4419-for-covid-19/
https://www.globenewswire.com/news-release/2020/05/13/2033075/0/en/Galera-Therapeutics-Announces-New-Data-from-the-Phase-2b-Trial-on-the-Effect-of-Avasopasem-Manganese-on-Cisplatin-Induced-Chronic-Kidney-Disease-to-be-Presented-at-ASCO-2020-Virtua.html
https://www.globenewswire.com/news-release/2020/04/30/2025773/0/en/Galera-Therapeutics-Announces-Presentation-of-Avasopasem-Manganese-Data-at-ASCO-2020-Virtual-Scientific-Program.html
https://www.globenewswire.com/news-release/2020/02/27/1992247/0/en/Galera-Therapeutics-Announces-Avasopasem-Manganese-GC4419-Maintained-Anti-Cancer-Benefit-of-Chemoradiotherapy-for-Head-and-Neck-Cancer-While-Substantially-Reducing-Radiation-Induce.html
Market Place
Share 
